Pfizer, Viagra’s original manufacturer, aggressively defended its patent, triggering numerous legal challenges from generic drug companies seeking to enter the market. These battles frequently involved complex arguments about patent validity and scope, delaying generic entry. For example, Pfizer successfully extended Viagra’s patent life through various means, including supplementary patent applications covering new formulations or uses.
Data Protection Certificates also played a crucial role. These certificates, granted in many countries, offer an additional period of exclusivity after a drug’s initial patent expires, protecting the originator from generic competition. This exclusivity period, often lasting several years, further delayed the arrival of generic Viagra.
Strategic litigation, including appeals and counter-suits, significantly increased the time required for generic manufacturers to secure approvals and launch their products. The cost and length of these legal battles created a high barrier to entry for smaller companies.
Ultimately, the combined effect of patent extensions and legal maneuvering resulted in a prolonged period of market exclusivity for Pfizer, significantly delaying the availability of generic Viagra. This highlights the significant impact of intellectual property rights on drug pricing and access.
